<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00710138</url>
  </required_header>
  <id_info>
    <org_study_id>19072</org_study_id>
    <nct_id>NCT00710138</nct_id>
  </id_info>
  <brief_title>Cobalamin Status in Young Children With Developmental Delay</brief_title>
  <official_title>Cobalamin Status in Young Children With Developmental Delay and Regression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Norwegian Foundation for Health and Rehabilitation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Foundation to Promote Research into Functional Vitamin B12 Deficiency, Bergen, Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Haukeland University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      During fetal life and infancy, an adequate cobalamin status is important for normal growth
      and central nervous system development. During the last years we have detected cobalamin
      deficiency in a number of infants admitted to the Pediatric Department with various symptoms,
      including neurological symptoms and feeding problems. Cobalamin treatment is given to the
      infants with biochemical cobalamin deficiency, and leads to loss of symptoms and in improved
      physical condition.

      In this study we want to establish the prevalence of cobalamin deficiency in infants with
      developmental delay and regression and other vague neurological symptoms. Cobalamin status
      will be investigated in all children aged 8 months and younger, admitted to the Pediatric
      Department with these symptoms. In a randomised intervention trial we will evaluate the
      effect of cobalamin supplementation in children with these symptoms and metabolic evidence of
      impaired cobalamin status.

      Study hypothesis: Cobalamin treatment given to the infants with biochemical cobalamin
      deficiency, will lead to loss of symptoms and in improved physical condition.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Outcome Measure: Changes in cobalamin and folate status, including metabolic markers, hematological parameters, neurological evaluation and growth parameters</measure>
    <time_frame>Reevalutation after 4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maternal evaluation of infant behaviour</measure>
    <time_frame>After 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Vitamin B 12 Deficiency</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma) given as a single intramuscular injection. The syringe is covered so it is impossible to see whether or not it contains any substance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The controls receive an intramuscular &quot;injection&quot;, however, it is only an introduction of the needle into the muscle, but no injections are given. The syringe is covered so it is impossible to see whether or not it contains any substance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma)</intervention_name>
    <description>400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma), as a single intramuscular injection</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Vitamin B12</other_name>
    <other_name>Cobalamin</other_name>
    <other_name>B vitamins</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children below 8 months of age

          -  Clinical diagnosis or symptoms: developmental delay and regression and other vague
             neurological symptoms

        Exclusion Criteria:

          -  Children with syndromic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>8 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne-Lise Bjørke Monsen, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laboratory of Clinical Biochemistry, Haukeland University Hospital, N-5021 Bergen, Norway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Per Magne Ueland, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Department of Internal Medicine, University of Bergen, 5021 Armauer Hanssen Hus, Bergen, NORWAY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Pediatrics, Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>Bjørke Monsen AL, Ueland PM, Vollset SE, Guttormsen AB, Markestad T, Solheim E, Refsum H. Determinants of cobalamin status in newborns. Pediatrics. 2001 Sep;108(3):624-30. Erratum in: Pediatrics 2002 Oct;110(4):853.</citation>
    <PMID>11533328</PMID>
  </reference>
  <reference>
    <citation>Graham SM, Arvela OM, Wise GA. Long-term neurologic consequences of nutritional vitamin B12 deficiency in infants. J Pediatr. 1992 Nov;121(5 Pt 1):710-4.</citation>
    <PMID>1432418</PMID>
  </reference>
  <reference>
    <citation>Casella EB, Valente M, de Navarro JM, Kok F. Vitamin B12 deficiency in infancy as a cause of developmental regression. Brain Dev. 2005 Dec;27(8):592-4.</citation>
    <PMID>16310594</PMID>
  </reference>
  <reference>
    <citation>Grattan-Smith PJ, Wilcken B, Procopis PG, Wise GA. The neurological syndrome of infantile cobalamin deficiency: developmental regression and involuntary movements. Mov Disord. 1997 Jan;12(1):39-46.</citation>
    <PMID>8990052</PMID>
  </reference>
  <reference>
    <citation>Rosenblatt DS, Whitehead VM. Cobalamin and folate deficiency: acquired and hereditary disorders in children. Semin Hematol. 1999 Jan;36(1):19-34. Review.</citation>
    <PMID>9930566</PMID>
  </reference>
  <reference>
    <citation>Bjørke-Monsen AL, Torsvik I, Saetran H, Markestad T, Ueland PM. Common metabolic profile in infants indicating impaired cobalamin status responds to cobalamin supplementation. Pediatrics. 2008 Jul;122(1):83-91. doi: 10.1542/peds.2007-2716.</citation>
    <PMID>18595990</PMID>
  </reference>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2008</study_first_submitted>
  <study_first_submitted_qc>July 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2008</study_first_posted>
  <last_update_submitted>August 13, 2010</last_update_submitted>
  <last_update_submitted_qc>August 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Anne-Lise Bjørke Monsen</name_title>
    <organization>Haukeland University Hospital</organization>
  </responsible_party>
  <keyword>Cobalamin deficiency</keyword>
  <keyword>Infant</keyword>
  <keyword>Nutrition</keyword>
  <keyword>Cobalamin supplementation</keyword>
  <keyword>Neurodevelopment</keyword>
  <keyword>Neurological symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin B 12 Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin B 12</mesh_term>
    <mesh_term>Hydroxocobalamin</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

